Cargando…

Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications

Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve f...

Descripción completa

Detalles Bibliográficos
Autores principales: Duque, Alice, Mediano, Mauro Felippe Felix, De Lorenzo, Andrea, Rodrigues Jr, Luiz Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192252/
https://www.ncbi.nlm.nih.gov/pubmed/34168733
http://dx.doi.org/10.4239/wjd.v12.i6.855
_version_ 1783706021982633984
author Duque, Alice
Mediano, Mauro Felippe Felix
De Lorenzo, Andrea
Rodrigues Jr, Luiz Fernando
author_facet Duque, Alice
Mediano, Mauro Felippe Felix
De Lorenzo, Andrea
Rodrigues Jr, Luiz Fernando
author_sort Duque, Alice
collection PubMed
description Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve fibers, which innervate the heart and blood vessels and promote alterations in cardiovascular autonomic control. The entire mechanism is still not elucidated, but several aspects of the pathophysiology of CAN have already been described, such as the production of advanced glycation end products, reactive oxygen species, nuclear factor kappa B, and pro-inflammatory cytokines. This microvascular complication is an important risk factor for silent myocardial ischemia, chronic kidney disease, myocardial dysfunction, major cardiovascular events, cardiac arrhythmias, and sudden death. It has also been suggested that, compared to other traditional cardiovascular risk factors, CAN progression may have a greater impact on cardiovascular disease development. However, CAN might be subclinical for several years, and a late diagnosis increases the mortality risk. The duration of the transition period from the subclinical to clinical stage remains unknown, but the progression of CAN is associated with a poor prognosis. Several tests can be used for CAN diagnosis, such as heart rate variability (HRV), cardiovascular autonomic reflex tests, and myocardial scintigraphy. Currently, it has already been described that CAN could be detected even during the subclinical stage through a reduction in HRV, which is a non-invasive test with a lower operating cost. Therefore, considering that diabetes mellitus is a global epidemic and that diabetic neuropathy is the most common chronic complication of diabetes, the early identification and treatment of CAN could be a key point to mitigate the morbidity and mortality associated with this long-lasting condition.
format Online
Article
Text
id pubmed-8192252
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-81922522021-06-23 Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications Duque, Alice Mediano, Mauro Felippe Felix De Lorenzo, Andrea Rodrigues Jr, Luiz Fernando World J Diabetes Minireviews Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve fibers, which innervate the heart and blood vessels and promote alterations in cardiovascular autonomic control. The entire mechanism is still not elucidated, but several aspects of the pathophysiology of CAN have already been described, such as the production of advanced glycation end products, reactive oxygen species, nuclear factor kappa B, and pro-inflammatory cytokines. This microvascular complication is an important risk factor for silent myocardial ischemia, chronic kidney disease, myocardial dysfunction, major cardiovascular events, cardiac arrhythmias, and sudden death. It has also been suggested that, compared to other traditional cardiovascular risk factors, CAN progression may have a greater impact on cardiovascular disease development. However, CAN might be subclinical for several years, and a late diagnosis increases the mortality risk. The duration of the transition period from the subclinical to clinical stage remains unknown, but the progression of CAN is associated with a poor prognosis. Several tests can be used for CAN diagnosis, such as heart rate variability (HRV), cardiovascular autonomic reflex tests, and myocardial scintigraphy. Currently, it has already been described that CAN could be detected even during the subclinical stage through a reduction in HRV, which is a non-invasive test with a lower operating cost. Therefore, considering that diabetes mellitus is a global epidemic and that diabetic neuropathy is the most common chronic complication of diabetes, the early identification and treatment of CAN could be a key point to mitigate the morbidity and mortality associated with this long-lasting condition. Baishideng Publishing Group Inc 2021-06-15 2021-06-15 /pmc/articles/PMC8192252/ /pubmed/34168733 http://dx.doi.org/10.4239/wjd.v12.i6.855 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Duque, Alice
Mediano, Mauro Felippe Felix
De Lorenzo, Andrea
Rodrigues Jr, Luiz Fernando
Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
title Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
title_full Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
title_fullStr Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
title_full_unstemmed Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
title_short Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
title_sort cardiovascular autonomic neuropathy in diabetes: pathophysiology, clinical assessment and implications
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192252/
https://www.ncbi.nlm.nih.gov/pubmed/34168733
http://dx.doi.org/10.4239/wjd.v12.i6.855
work_keys_str_mv AT duquealice cardiovascularautonomicneuropathyindiabetespathophysiologyclinicalassessmentandimplications
AT medianomaurofelippefelix cardiovascularautonomicneuropathyindiabetespathophysiologyclinicalassessmentandimplications
AT delorenzoandrea cardiovascularautonomicneuropathyindiabetespathophysiologyclinicalassessmentandimplications
AT rodriguesjrluizfernando cardiovascularautonomicneuropathyindiabetespathophysiologyclinicalassessmentandimplications